Limited impact of Elexacaftor/Tezacaftor/Ivacaftor on CPET outcomes in an Italian cohort of people with Cystic Fibrosis: reinforcing the essential role of exercise training [0.03%]
Elexacaftor/Tezacaftor/Ivacaftor对意大利囊性纤维化患者循环运动试验结果的影响有限：强化锻炼训练的作用不可缺少：一项队列研究
Mariangela Retucci,Andrea Gramegna,Simone Gambazza et al.
Mariangela Retucci et al.
Background: Elexacaftor/Tezacaftor/Ivacaftor (ETI) is changing life quality and expectancy of people with Cystic Fibrosis (pwCF). Exercise has a pivotal role in improving health of pwCF and proved to be a reliable indicat...
Stool and symptom testing in ColoREctal Evaluation for Neoplasia in Cystic Fibrosis (SCREEN-CF) [0.03%]
囊性纤维化结直肠肿瘤筛查(SCREEN-CF)中的粪便和症状检测项目
Nicole A Taylor,Sheila Sivam,Josie van Dorst et al.
Nicole A Taylor et al.
Background: People with cystic fibrosis (pwCF) have increased colorectal cancer (CRC) risk. Colonoscopy is recommended, yet CF comorbidities increase complexity and risk. ...
Economic impact of elexacaftor/tezacaftor/ivacaftor on healthcare expenditure in Canada [0.03%]
Elexacaftor/Tezacaftor/Ivacaftor对加拿大医疗保健支出的经济影响
Stephen E Congly,Ranjani Somayaji,Michael D Parkins et al.
Stephen E Congly et al.
The introduction of elexacaftor/tezacaftor/ivacaftor (ETI) has led to improved outcomes and survival in patients living with cystic fibrosis (PwCF) although imposes a substantial economic burden. Despite the reduced healthcare utilization t...
Lung transplant for CF: Low lung bacterial burden and immune mediators in year one associate with clad development [0.03%]
囊性纤维化患者的肺移植术后一年内肺细菌负荷低和免疫介质与小气道功能保留有关
Samantha A Whiteside,John E McGinniss,Rebecca A Deek et al.
Samantha A Whiteside et al.
Background: Lung transplantation is commonly required for advanced lung disease in cystic fibrosis (CF). Long-term lung allograft survival is limited primarily by chronic lung allograft dysfunction (CLAD), and microbial f...
Sexual health experiences and care utilization of males with cystic fibrosis [0.03%]
囊性纤维化男性的性健康经历和医疗服务利用情况
Traci M Kazmerski,Olivia M Stransky,Catherine E Wright et al.
Traci M Kazmerski et al.
Background: Males with cystic fibrosis (MwCF) face many sexual health concerns that have been understudied. We compared sexual health experiences and care utilization of MwCF to the general population and defined CF-relat...
Letter to the editor: Semaglutide-associated recurrent distal intestinal obstruction in cystic fibrosis [0.03%]
读者来信：司美格鲁肽致囊性纤维化患者复发性远端肠梗阻
Rita Kamoua,Kristen Paradine,Luke McCoy
Rita Kamoua
Cystic fibrosis-related liver disease in children- A vascular or a biliary disease? [0.03%]
儿童囊性纤维化相关肝病是一种血管疾病还是一种胆道疾病？
Amit Saha,Michael Stormon,Peter Lewindon et al.
Amit Saha et al.
Background: Cystic fibrosis-related liver disease(CFLD) has long been thought to be secondary to CFTR dysfunction in the biliary epithelial cells causing hepatobiliary complications,eventually progressing to cirrhosis. Ho...
Identity, functional consequences, and context effects of amino acids inserted during suppression of CFTR nonsense mutations [0.03%]
插入囊性纤维化跨膜传导调节器终止密码子突变的氨基酸的身份、功能后果及背景效应
Kari Thrasher,Jianguo Chen,Lianwu Fu et al.
Kari Thrasher et al.
Background: Cystic fibrosis patients who carry a CFTR nonsense allele often express negligible CFTR protein, and thus, are unresponsive to CFTR modulators. Nonsense suppression (also called readthrough) is an emerging the...
Real-world pancreatic function recovery and fluctuation in young children with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor [0.03%]
年轻囊性纤维化患儿使用elexacaftor/tezacaftor/ivacaftor的实际胰腺功能恢复与波动情况
Laura Schembri,Delyth Jones,Siân Bentley et al.
Laura Schembri et al.
Background: Clinical trials showed improved faecal elastase (FE-1) levels in younger children with cystic fibrosis (cwCF) on elexacaftor/tezacaftor/ivacaftor (ETI). Lower sweat chloride has been linked to better clinical ...
Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI) [0.03%]
利福布汀与艾沙卡福特/-tezacaftor/维卡福特(ETI)药物相互作用的评价
Madeline Sanders,Eunjin Hong,Peter S Chung et al.
Madeline Sanders et al.
Background: Rifampin is a guideline-recommended treatment for nontuberculous mycobacteria infections; however, it is a strong inducer of CYP3A metabolism and therefore is contraindicated in patients receiving elexacaftor/...